1451 related articles for article (PubMed ID: 29105511)
1. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
2. Precision medicine becomes reality-tumor type-agnostic therapy.
Yan L; Zhang W
Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
[TBL] [Abstract][Full Text] [Related]
3. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL
J Immunother Cancer; 2018 May; 6(1):35. PubMed ID: 29754585
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Marcus L; Lemery SJ; Keegan P; Pazdur R
Clin Cancer Res; 2019 Jul; 25(13):3753-3758. PubMed ID: 30787022
[TBL] [Abstract][Full Text] [Related]
5. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.
Hong YD; Enewold L; Halpern MT; Zeruto C; Mariotto AB
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5745. PubMed ID: 38156547
[TBL] [Abstract][Full Text] [Related]
6. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
Seligson ND; Knepper TC; Ragg S; Walko CM
Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
[TBL] [Abstract][Full Text] [Related]
7. Drug Development, Trial Design, and Endpoints in Oncology: Adapting to Rapidly Changing Science.
Blumenthal GM; Goldberg KB; Pazdur R
Clin Pharmacol Ther; 2017 May; 101(5):572-574. PubMed ID: 28074476
[TBL] [Abstract][Full Text] [Related]
8. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
9. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
Kwok M; Foster T; Steinberg M
Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
[TBL] [Abstract][Full Text] [Related]
10. FDA Approvals of Oncology Drugs for Tissue-Agnostic Indications.
Zettler ME
Target Oncol; 2023 Sep; 18(5):777-792. PubMed ID: 37477750
[TBL] [Abstract][Full Text] [Related]
11. Making precision oncology the standard of care.
The Lancet Oncology
Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
[No Abstract] [Full Text] [Related]
12. FDA's Flexibility in Subpart H Approvals: Assessing Quantum of Effectiveness Evidence.
Sasinowski FJ; Varond AJ
Food Drug Law J; 2016 Aug; 71(1):135-157. PubMed ID: 29693934
[TBL] [Abstract][Full Text] [Related]
13. Extending the US Food and Drug Administration's Postmarket Authorities.
Fernandez Lynch H; Sachs RE; Lee S; Herder M; Ross JS; Ramachandran R
JAMA Health Forum; 2023 Jun; 4(6):e231313. PubMed ID: 37294583
[TBL] [Abstract][Full Text] [Related]
14. Tissue-Agnostic Drug Development: A New Path to Drug Approval.
Thein KZ; Lemery SJ; Kummar S
Cancer Discov; 2021 Sep; 11(9):2139-2144. PubMed ID: 34479971
[TBL] [Abstract][Full Text] [Related]
15. The First Year of the Food and Drug Administration Oncology Center of Excellence: Landmark Approvals in a Dynamic Regulatory Environment.
Goldberg KB; Blumenthal GM; Pazdur R
Cancer J; 2018; 24(3):131-135. PubMed ID: 29794538
[TBL] [Abstract][Full Text] [Related]
16. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
17. Loose Regulatory Standards Portend a New Era of Imprecision Oncology.
Khaki AR
Cancer Invest; 2021 Feb; 39(2):120-123. PubMed ID: 33290099
[TBL] [Abstract][Full Text] [Related]
18. An appraisal of drug development timelines in the Era of precision oncology.
Jardim DL; Schwaederle M; Hong DS; Kurzrock R
Oncotarget; 2016 Aug; 7(33):53037-53046. PubMed ID: 27419632
[TBL] [Abstract][Full Text] [Related]
19. Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines.
Pregelj L; Hwang TJ; Hine DC; Siegel EB; Barnard RT; Darrow JJ; Kesselheim AS
Health Aff (Millwood); 2018 May; 37(5):724-731. PubMed ID: 29733717
[TBL] [Abstract][Full Text] [Related]
20. FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs.
Kluetz PG; Keegan P; Demetri GD; Thornton K; Sul J; Kim J; Katzen H; Burke LB; Harvey RD; Alebachew E; Agrawal S; Nair A; Donoghue M; Pierce WF; Shord SS; Gao JJ; Pazdur R
Clin Cancer Res; 2021 Feb; 27(4):916-921. PubMed ID: 33257426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
